ClinicalTrials.gg
Active, not recruitingNCT03462719GLOWUpdated Nov 3, 2026Results posted

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

A Phase 3 interventional study of Ibrutinib and Venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 88 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Updated Nov 3, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
211
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
15th of 83
211 · median 44
Started
2018
with 7 others
Phase 3
14 of 83
none open now
Primary completion
2021-02
later than 7 of 27 live
Registered
58th of 83
by date
Lead sponsor
8 of 83
Janssen Research & Development, LLC

Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 15th largest by enrollment, is one of 8 that started in 2018, is one of 14 in phase 3, reaches primary completion later than 7 of the 27 other live ones, and was the 58th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).

03

Conditions studied

  • Leukemia, Lymphocytic, Chronic, B-Cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants who are: (a) greater than or equal to (>=) 65 years old or, (b) 18 to 64 years old and have at least 1 of the following:

    1. Cumulative Illness Rating Scale (CIRS) score > 6
    2. (CrCl) estimated less than (\<) 70 milliliter per minute (mL/min) using Cockcroft-Gault equation
  • Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that meets International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria
  • Measurable nodal disease (by computed tomography [CT]), defined as at least one lymph node > 1.5 centimeter (cm) in longest diameter
  • (ECOG) Performance Status (PS) Grade less than or equal to (\<=) 2
  • Active CLL/SLL requiring treatment per the iwCLL criteria

Exclusion criteria

Exclusion Criteria:

  • Prior anti-leukemic therapy for CLL or SLL
  • Presence of deletion of the short arm of chromosome 17 (del17p) or known TP53 mutation detected at a threshold of >10 percent (%) variable allele frequency (VAF)
  • Major surgery within 4 weeks of first dose of study treatment
  • Known bleeding disorders (example, von Willebrand's disease or hemophilia)
  • Central nervous system (CNS) involvement or suspected Richter's syndrome
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
211 participants (actual)

Study arms

  • Experimental
    Treatment Arm A: Ibrutinib and Venetoclax (I+VEN)

    Participants will initially receive ibrutinib (420 mg \[milligrams\]/day) for 3 cycles. Venetoclax dose ramp up (from 20 to 400 mg over 5 weeks) will begin at Cycle 4 and the combination of ibrutinib and venetoclax will be given for 12 cycles (each cycle is equivalent to 28 days). Participants who subsequently develop progressive disease may enter to Subsequent Therapy Phase to receive single-agent ibrutinib until disease progression or unacceptable toxicity.

    Drug: Ibrutinib · Drug: Venetoclax · Drug: Ibrutinib (as Subsequent Therapy)

  • Active comparator
    Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb)

    Participants will receive chlorambucil and obinutuzumab (G-Clb) for 6 cycles. Participants will receive obinutuzumab, 1000 mg intravenously (IV) on Days 1, 8 and 15 of Cycle 1, and on Day 1 of Cycles 2 to 6 and chlorambucil 0.5 milligrams per kilogram (mg/kg) body weight, on Days 1 and 15 of Cycles 1 to 6. Participants who subsequently develop progressive disease may enter to Subsequent Therapy Phase to receive single-agent ibrutinib until disease progression or unacceptable toxicity.

    Drug: Chlorambucil · Drug: Obinutuzumab · Drug: Ibrutinib (as Subsequent Therapy)

Interventions

  • Participants will receive ibrutinib 420 mg orally once daily up to 15 cycles.

  • Participants will receive venetoclax in combination with ibrutinib for a total of 12 cycles, beginning at Cycle 4. For the first 5 weeks of venetoclax treatment, the treatment dose will be ramped up from 20 to 400 mg.

  • Participants will receive chlorambucil at a dose of 0.5 mg/kg body weight on Days 1 and 15 of Cycles 1 to 6.

  • Participant will receive obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, and Day 1 of Cycles 2 to 6.

  • Participants will receive ibrutinib 420 mg orally once daily until disease progression or unacceptable toxicity during the subsequent therapy phase.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS: time between date of randomization and date of disease progression, as assessed by IRC, or date of death due to any cause, whichever occurs first, regardless of use of subsequent anti-cancer therapy prior to PD or death using iWCLL2008 criteria : New enlarged lymph nodes \>15 mm, new hepatomegaly or splenomegaly, or other organ infiltrates, bone lesion, ascites or pleural effusion due to CLL; \>=50% increase in longest diameter (LDi) from nadir in existing lymph node (LDi \>15 mm) or \>=50% increase from nadir in sum of diameters of multiple nodes (and at least 1 node with LDi \>15 mm); \>=50% increase from nadir in enlargement of liver/spleen; \>=50% increase from baseline in lymphocyte count (ALC; to \>=5\*10\^9/L); or \>=50% increase from nadir in ALC in \>=2 serial assessments if ALC is \>=30000\*10\^9/L and lymphocyte doubling time is rapid unless considered treatment-related lymphocytosis; new cytopenia attributable to CLL; transformation to more aggressive histology.

    Time frame: Up to 2 years 10 months

Secondary outcomes

  1. Minimal Residual Disease (MRD) Negative Rate

    MRD-negative rate is defined as the percentage of participants who achieved MRD-negative status (that is, less than \[\<\] 1 chronic lymphocytic leukemia (CLL) cell per 10,000 leukocytes or \<0.01 percentage \[%\]) in the bone marrow as assessed by next-generation sequencing (NGS). Participants with missing MRD data were considered MRD positive.

    Time frame: Up to 2 years 10 months

  2. Complete Response Rate (CRR)

    Complete response rate is defined as the percentage of participants who achieved complete response or complete response with an incomplete marrow recovery (CRi) on or prior to initiation of subsequent anti-leukemic therapy per the IRC assessment. International Workshop on Chronic Lymphocytic Leukemia (iWCLL) 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \>1.5\*10\^9/liter (L), platelets \>100\*10\^9/L, Hgb \>11 gram per deciliter (g/dL), absolute lymphocyte count \<4000/microliter (mcL) and normocellular bone marrow with \<30% lymphocytes and no B lymphoid nodules; CRi- CR with incomplete recovery of bone marrow.

    Time frame: Up to 2 years 10 months

  3. Overall Response Rate (ORR)

    ORR: percentage of participants who achieved best overall response of either CR, CRi, nodular PR (nPR) and partial response (PR). iWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \>1.5\*10\^9/liter (L), platelets \>100\*10\^9/L, Hgb \>11 g/dL and ALC \<4000/mcL, normocellular bone marrow with \<30% lymphocytes and no B lymphoid nodules; CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but bone marrow biopsy shows B-lymphoid nodules (reflecting residual disease); PR-2 of following when abnormal at baseline: \>=50% decrease in ALC, \>=50% decrease in sum of products of multiple nodes, \>=50% decrease in enlargement of spleen or liver; and 1 of following: neutrophils \>1.5\*10\^9/L, Platelets \>100\*10\^9/L and Hgb\>11 g/dL or \>=50% improvement over baseline in any of these; 50% reduction in bone marrow infiltrates or B lymphoid nodules; no new enlarged nodes or new hepatosplenomegaly.

    Time frame: Up to 2 years 10 months

  4. Overall Survival (OS)

    OS is defined as the time from date of randomization to date of death from any cause.

    Time frame: Up to 4 years 10 months

  5. Duration of Response (DOR)

    DOR is defined as the interval between the date of initial documentation of a response including partial response with lymphocytosis (PRL) and the date of first documented evidence of PD or death or date of censoring per the IRC assessment. iWCLL 2008 criteria for PD: New enlarged nodes \>1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; \>= 50% increase from nadir in existing lymph node or \>=50% increase from nadir in sum of product of diameters of multiple nodes; \>=50% increase from nadir in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (and to \>=5\*10\^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology.

    Time frame: Up to 2 years 10 months

  6. Time-to-Next Treatment

    Time-to-next treatment was measured from the date of randomization to the start date of any subsequent anti-leukemic therapy.

    Time frame: Up to 2 years 10 months

  7. Time to Worsening as Measured by Using EuroQol 5 Dimension 5 Level Questionnaire (EQ-5D-5L)

    Time to worsening= time interval (months) from randomization to first observation of deterioration. EQ-5D-5L consists of a 5-item descriptive system and the EuroQol visual analog scale (EQ-5D VAS). EQ-5D-VAS self-rating records respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Worsening is defined as a decrease of \>= 7 points (on a 0-100 scale). EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe participant's current health state. Responses for 5 dimensions are combined into a 5-digit number describing respondents health state that can be converted into a single index value or utility score (using the United Kingdom weights), ranging from -1 to 1, where lower scores indicate a worse health status. Worsening is defined as a decrease of \>=0.08 points (on a 0-1 scale).

    Time frame: Up to 2 years 10 months

  8. Time to Worsening Measured by European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ)-C30)

    Time to worsening= time interval from randomization to first observation of deterioration. EORTC QLQ-C30 includes 30 separate items: 5 functional scales (physical, role, emotional, cognitive, and social Functioning), 1 global health status (GHS) and QoL scale, 3 symptom scales (fatigue, nausea/vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Each item, except GHS, is answered on 4-point scale (1=not at all to 4=very much) and GHS is measured on 1-7 scale: 1=very poor and 7=excellent. Scores derived using validated scoring algorithms as per EORTC QLQ-C30 Manual and linearly transformed in a range from 0-100. For functional and global QoL scales, higher scores=better level of functioning/QoL. For symptom-oriented scales, higher score=more severe symptoms. Worsening in functional and global health scores=decrease of \>=10 points (on 0-100 scale) and in symptom scores=increase of \>=10 points (on 0-100 scale).

    Time frame: Up to 2 years 10 months

  9. Time to Worsening and Time to Improvement as Measured by Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Total Score

    Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). Time to Worsening is defined as time interval (months) from randomization to first observation of deterioration. Worsening is defined as a decrease \>= 3 points (on a 0-52 scale). Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. Improvement is defined as an increase \>=3 points (on a 0-52 scale).

    Time frame: Up to 2 years 10 months

  10. Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability

    An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

    Time frame: Up to 4 years 10 months

  11. Number of Participants With Abnormal Clinical Laboratory Findings

    Number of participants with abnormal clinical laboratory findings (hematology and serum chemistry) were reported.

    Time frame: Up to 4 years 10 months

  12. Percentage of Participants With Sustained Hemoglobin Improvement

    Sustained hemoglobin improvement is defined as the percentage of participants who achieved an increase in hemoglobin levels from baseline by \>= 2 grams per deciliter (g/dL) and lasts for at least 56 days without blood transfusion or growth factors.

    Time frame: Up to 2 years 10 months

  13. Percentage of Participants With Sustained Platelet Improvement

    Sustained platelet improvement is defined as the percentage of participants who achieved an increase in platelet levels from baseline by \>= 50% and lasts for at least 56 days without blood transfusion or growth factors.

    Time frame: Up to 2 years 10 months

  14. Plasma Concentration of Ibrutinib and Venetoclax

    Plasma concentrations of ibrutinib and venetoclax were determined by validated liquid chromatography-tandem mass spectrometry.

    Time frame: Ibrutinib: Pre-dose-Day 1 of Cycles 2, 3, 5 and 6 (each cycle is defined as 28 days), Venetoclax: Pre-dose-Day 1 of Cycles 5 and 6

07

Results

Posted Mar 28, 2022

Participant flow

Participant flow — Overall Study
MilestoneTreatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)
Started106105
Completed1530
Not completed9175
Withdrew: Withdrawal by subject43
Withdrew: Ongoing8772

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS: time between date of randomization and date of disease progression, as assessed by IRC, or date of death due to any cause, whichever occurs first, regardless of use of subsequent anti-cancer therapy prior to PD or death using iWCLL2008 criteria : New enlarged lymph nodes \>15 mm, new hepatomegaly or splenomegaly, or other organ infiltrates, bone lesion, ascites or pleural effusion due to CLL; \>=50% increase in longest diameter (LDi) from nadir in existing lymph node (LDi \>15 mm) or \>=50% increase from nadir in sum of diameters of multiple nodes (and at least 1 node with LDi \>15 mm); \>=50% increase from nadir in enlargement of liver/spleen; \>=50% increase from baseline in lymphocyte count (ALC; to \>=5\*10\^9/L); or \>=50% increase from nadir in ALC in \>=2 serial assessments if ALC is \>=30000\*10\^9/L and lymphocyte doubling time is rapid unless considered treatment-related lymphocytosis; new cytopenia attributable to CLL; transformation to more aggressive histology.

Time frame:
Up to 2 years 10 months
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsTreatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)
Progression Free Survival (PFS)NA (31.24 to NA)20.96 (16.59 to 24.67)
Statistical analysis
  • Treatment Arm A (Ibrutinib + Venetoclax) vs Treatment Arm B (Chlorambucil + Obinutuzumab) · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.216 · 95% CI 0.131 to 0.357
SecondaryMinimal Residual Disease (MRD) Negative Rate

MRD-negative rate is defined as the percentage of participants who achieved MRD-negative status (that is, less than \[\<\] 1 chronic lymphocytic leukemia (CLL) cell per 10,000 leukocytes or \<0.01 percentage \[%\]) in the bone marrow as assessed by next-generation sequencing (NGS). Participants with missing MRD data were considered MRD positive.

Time frame:
Up to 2 years 10 months
Reported as:
Number · Percentage of participants
Minimal Residual Disease (MRD) Negative Rate
Percentage of participantsTreatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)
Minimal Residual Disease (MRD) Negative Rate55.7 (46.2 to 65.1)21.0 (13.2 to 28.7)
SecondaryComplete Response Rate (CRR)

Complete response rate is defined as the percentage of participants who achieved complete response or complete response with an incomplete marrow recovery (CRi) on or prior to initiation of subsequent anti-leukemic therapy per the IRC assessment. International Workshop on Chronic Lymphocytic Leukemia (iWCLL) 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \>1.5\*10\^9/liter (L), platelets \>100\*10\^9/L, Hgb \>11 gram per deciliter (g/dL), absolute lymphocyte count \<4000/microliter (mcL) and normocellular bone marrow with \<30% lymphocytes and no B lymphoid nodules; CRi- CR with incomplete recovery of bone marrow.

Time frame:
Up to 2 years 10 months
Reported as:
Number · Percentage of Participants
Complete Response Rate (CRR)
Percentage of ParticipantsTreatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)
Complete Response Rate (CRR)38.7 (29.4 to 48.0)11.4 (5.3 to 17.5)
SecondaryOverall Response Rate (ORR)

ORR: percentage of participants who achieved best overall response of either CR, CRi, nodular PR (nPR) and partial response (PR). iWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \>1.5\*10\^9/liter (L), platelets \>100\*10\^9/L, Hgb \>11 g/dL and ALC \<4000/mcL, normocellular bone marrow with \<30% lymphocytes and no B lymphoid nodules; CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but bone marrow biopsy shows B-lymphoid nodules (reflecting residual disease); PR-2 of following when abnormal at baseline: \>=50% decrease in ALC, \>=50% decrease in sum of products of multiple nodes, \>=50% decrease in enlargement of spleen or liver; and 1 of following: neutrophils \>1.5\*10\^9/L, Platelets \>100\*10\^9/L and Hgb\>11 g/dL or \>=50% improvement over baseline in any of these; 50% reduction in bone marrow infiltrates or B lymphoid nodules; no new enlarged nodes or new hepatosplenomegaly.

Time frame:
Up to 2 years 10 months
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsTreatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)
Overall Response Rate (ORR)86.8 (80.3 to 93.2)84.8 (77.9 to 91.6)
SecondaryOverall Survival (OS)

OS is defined as the time from date of randomization to date of death from any cause.

Time frame:
Up to 4 years 10 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsTreatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
SecondaryDuration of Response (DOR)

DOR is defined as the interval between the date of initial documentation of a response including partial response with lymphocytosis (PRL) and the date of first documented evidence of PD or death or date of censoring per the IRC assessment. iWCLL 2008 criteria for PD: New enlarged nodes \>1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; \>= 50% increase from nadir in existing lymph node or \>=50% increase from nadir in sum of product of diameters of multiple nodes; \>=50% increase from nadir in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (and to \>=5\*10\^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology.

Time frame:
Up to 2 years 10 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsTreatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)
Duration of Response (DOR)28.85 (28.68 to NA)21.13 (15.93 to 25.10)
SecondaryTime-to-Next Treatment

Time-to-next treatment was measured from the date of randomization to the start date of any subsequent anti-leukemic therapy.

Time frame:
Up to 2 years 10 months
Reported as:
Median · Months
Time-to-Next Treatment
MonthsTreatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)
Time-to-Next TreatmentNA (NA to NA)NA (31.54 to NA)
SecondaryTime to Worsening as Measured by Using EuroQol 5 Dimension 5 Level Questionnaire (EQ-5D-5L)

Time to worsening= time interval (months) from randomization to first observation of deterioration. EQ-5D-5L consists of a 5-item descriptive system and the EuroQol visual analog scale (EQ-5D VAS). EQ-5D-VAS self-rating records respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Worsening is defined as a decrease of \>= 7 points (on a 0-100 scale). EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe participant's current health state. Responses for 5 dimensions are combined into a 5-digit number describing respondents health state that can be converted into a single index value or utility score (using the United Kingdom weights), ranging from -1 to 1, where lower scores indicate a worse health status. Worsening is defined as a decrease of \>=0.08 points (on a 0-1 scale).

Time frame:
Up to 2 years 10 months
Reported as:
Median · Months
Time to Worsening as Measured by Using EuroQol 5 Dimension 5 Level Questionnaire (EQ-5D-5L)
MonthsTreatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)
EQ-5D-5L: Visual Analogue Score8.34 (5.65 to NA)24.18 (11.27 to NA)
EQ-5D-5L: Utility Score14.29 (8.15 to NA)24.11 (8.34 to NA)
SecondaryTime to Worsening Measured by European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ)-C30)

Time to worsening= time interval from randomization to first observation of deterioration. EORTC QLQ-C30 includes 30 separate items: 5 functional scales (physical, role, emotional, cognitive, and social Functioning), 1 global health status (GHS) and QoL scale, 3 symptom scales (fatigue, nausea/vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Each item, except GHS, is answered on 4-point scale (1=not at all to 4=very much) and GHS is measured on 1-7 scale: 1=very poor and 7=excellent. Scores derived using validated scoring algorithms as per EORTC QLQ-C30 Manual and linearly transformed in a range from 0-100. For functional and global QoL scales, higher scores=better level of functioning/QoL. For symptom-oriented scales, higher score=more severe symptoms. Worsening in functional and global health scores=decrease of \>=10 points (on 0-100 scale) and in symptom scores=increase of \>=10 points (on 0-100 scale).

Time frame:
Up to 2 years 10 months
Reported as:
Median · Months
Time to Worsening Measured by European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ)-C30)
MonthsTreatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)
Global Health Status14.95 (8.38 to NA)24.18 (13.86 to NA)
Cognitive Functioning11.07 (5.95 to 24.05)14.03 (7.16 to NA)
Emotional FunctioningNA (17.31 to NA)25.00 (16.62 to NA)
Physical FunctioningNA (19.42 to NA)NA (14.03 to NA)
Role Functioning11.10 (6.28 to 14.95)8.48 (5.62 to 16.69)
Social Functioning11.10 (8.34 to 16.69)17.87 (11.07 to 25.30)
Fatigue (Symptom Scale)8.38 (5.62 to 14.95)17.87 (8.44 to NA)
Nausea/Vomiting (Symptom Scale)11.07 (8.28 to NA)NA (20.44 to NA)
Pain (Symptom Scale)8.31 (5.45 to 13.90)11.01 (5.65 to 17.87)
SecondaryTime to Worsening and Time to Improvement as Measured by Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Total Score

Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). Time to Worsening is defined as time interval (months) from randomization to first observation of deterioration. Worsening is defined as a decrease \>= 3 points (on a 0-52 scale). Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. Improvement is defined as an increase \>=3 points (on a 0-52 scale).

Time frame:
Up to 2 years 10 months
Reported as:
Median · Months
Time to Worsening and Time to Improvement as Measured by Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Total Score
MonthsTreatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)
Time to Worsening8.15 (3.98 to 10.94)14.03 (8.61 to NA)
Time to Improvement5.59 (3.81 to 11.20)3.75 (2.20 to 5.75)
SecondaryNumber of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability

An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Time frame:
Up to 4 years 10 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability
ParticipantsTreatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)
Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability10599
SecondaryNumber of Participants With Abnormal Clinical Laboratory Findings

Number of participants with abnormal clinical laboratory findings (hematology and serum chemistry) were reported.

Time frame:
Up to 4 years 10 months
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Laboratory Findings
ParticipantsTreatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)
Hematology: Absolute Neutrophils Counts (Decrease)8195
Hematology: Hemoglobin (Decrease)3842
Hematology: Platelets (Decrease)5278
Hematology: Any hemoglobin, platelet, or ANC decrease94103
Chemistry: Alanine Transaminase (ALT) (Increase)2226
Chemistry: Aspartate Aminotransferase (AST) (Increase)2330
Chemistry: Alkaline Phosphatase (Increase)1921
Chemistry: Bilirubin (Increase)3625
Chemistry: Creatinine (Increase)3317
Chemistry: Creatinine Clearance (Decrease)4017
Chemistry: Hypercalcemia133
Chemistry: Hypoalbuminemia3620
Chemistry: Hypocalcemia2730
Chemistry: Phosphate (Decrease)166
Chemistry: Potassium (Decrease)259
Chemistry: Potassium (Increase)3122
Chemistry: Sodium (Decrease)2526
Chemistry: Sodium (Increase)128
Chemistry: Uric Acid (Increase)3719
SecondaryPercentage of Participants With Sustained Hemoglobin Improvement

Sustained hemoglobin improvement is defined as the percentage of participants who achieved an increase in hemoglobin levels from baseline by \>= 2 grams per deciliter (g/dL) and lasts for at least 56 days without blood transfusion or growth factors.

Time frame:
Up to 2 years 10 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With Sustained Hemoglobin Improvement
Percentage of ParticipantsTreatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)
Percentage of Participants With Sustained Hemoglobin Improvement44.350.5
SecondaryPercentage of Participants With Sustained Platelet Improvement

Sustained platelet improvement is defined as the percentage of participants who achieved an increase in platelet levels from baseline by \>= 50% and lasts for at least 56 days without blood transfusion or growth factors.

Time frame:
Up to 2 years 10 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With Sustained Platelet Improvement
Percentage of ParticipantsTreatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)
Percentage of Participants With Sustained Platelet Improvement24.529.5
SecondaryPlasma Concentration of Ibrutinib and Venetoclax

Plasma concentrations of ibrutinib and venetoclax were determined by validated liquid chromatography-tandem mass spectrometry.

Time frame:
Ibrutinib: Pre-dose-Day 1 of Cycles 2, 3, 5 and 6 (each cycle is defined as 28 days), Venetoclax: Pre-dose-Day 1 of Cycles 5 and 6
Reported as:
Mean · Nanograms per milliliter (ng/mL)
Plasma Concentration of Ibrutinib and Venetoclax
Nanograms per milliliter (ng/mL)Treatment Arm A (Ibrutinib + Venetoclax)
Ibrutinib: Pre-dose Day 1 Cycle 2 (Ibrutinib Alone)5.70 ± 5.58
Ibrutinib: Pre-dose Day 1 Cycle 3 (Ibrutinib Alone)6.20 ± 7.78
Ibrutinib: Pre-dose Day 1 Cycle 5 (Ibrutinib and Venetoclax)6.37 ± 6.71
Ibrutinib: Pre-dose Day 1 Cycle 6 (Ibrutinib and Venetoclax)5.90 ± 6.74
Venetoclax: Pre-dose Day 1 Cycle 5 (Ibrutinib + Venetoclax)1139 ± 959
Venetoclax: Pre-dose Day 1 Cycle 6 (Ibrutinib + Venetoclax)1765 ± 1573

Adverse events

Collected over Up to 4 years 10 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Arm A (Ibrutinib + Venetoclax)17/106 (16%)49/106 (46.2%)98/106 (92.5%)
Treatment Arm B (Chlorambucil + Obinutuzumab)36/105 (34.3%)30/105 (28.6%)98/105 (93.3%)
Most frequent serious events
Showing 10 of 94
Most frequent serious events
EventTreatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)
Atrial FibrillationCardiac disorders7/1060/105
PneumoniaInfections and infestations6/1066/105
Febrile NeutropeniaBlood and lymphatic system disorders1/1063/105
Infusion Related ReactionInjury, poisoning and procedural complications0/1063/105
Tumour Lysis SyndromeMetabolism and nutrition disorders0/1063/105
AnaemiaBlood and lymphatic system disorders3/1062/105
Cardiac FailureCardiac disorders3/1060/105
DiarrhoeaGastrointestinal disorders3/1061/105
PyrexiaGeneral disorders1/1062/105
OverdoseInjury, poisoning and procedural complications0/1062/105
Most frequent other events
Showing 10 of 55
Most frequent other events
EventTreatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)
NeutropeniaBlood and lymphatic system disorders36/10656/105
DiarrhoeaGastrointestinal disorders53/10613/105
ThrombocytopeniaBlood and lymphatic system disorders12/10628/105
Infusion Related ReactionInjury, poisoning and procedural complications0/10628/105
NauseaGastrointestinal disorders28/10627/105
AnaemiaBlood and lymphatic system disorders17/10618/105
PyrexiaGeneral disorders6/10618/105
Urinary Tract InfectionInfections and infestations17/1064/105
RashSkin and subcutaneous tissue disorders17/1067/105
FatigueGeneral disorders16/10610/105

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)Total
Mean71 ± 8.0272 ± 6.1671.5 ± 7.01
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)Total
Female474289
Male5963122
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)Total
Hispanic or Latino134
Not Hispanic or Latino10199200
Unknown or Not Reported437
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White101101202
More than one race101
Unknown or Not Reported437
Region of Enrollment
Region of Enrollment(Participants)Treatment Arm A (Ibrutinib + Venetoclax)Treatment Arm B (Chlorambucil + Obinutuzumab)Total
BELGIUM729
CANADA71017
CZECH REPUBLIC91322
DENMARK7512
FRANCE437
ISRAEL61218
NETHERLANDS167
POLAND121022
RUSSIAN FEDERATION231639
SPAIN10919
SWEDEN202
TURKEY81321
UNITED KINGDOM8412
UNITED STATES224
08

Study locations

88 sites
09

References and documents

Publications

  • Kater AP, Owen C, Moreno C, Follows G, Munir T, Levin MD, Benjamini O, Janssens A, Osterborg A, Robak T, Simkovic M, Stevens D, Voloshin S, Vorobyev V, Ysebaert L, Qin R, Steele AJ, Schuier N, Baeten K, Caces DB, Niemann CU. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. NEJM Evid. 2022 Jul;1(7):EVIDoa2200006. doi: 10.1056/EVIDoa2200006. Epub 2022 May 13. PubMed 38319255 ↗
  • Niemann CU, Munir T, Moreno C, Owen C, Follows GA, Benjamini O, Janssens A, Levin MD, Robak T, Simkovic M, Voloshin S, Vorobyev V, Yagci M, Ysebaert L, Qi K, Qi Q, Sinet P, Parisi L, Srinivasan S, Schuier N, Baeten K, Howes A, Caces DB, Kater AP. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 Dec;24(12):1423-1433. doi: 10.1016/S1470-2045(23)00452-7. Epub 2023 Nov 6. PubMed 37944541 ↗
  • Moreno C, Solman IG, Tam CS, Grigg A, Scarfo L, Kipps TJ, Srinivasan S, Mali RS, Zhou C, Dean JP, Szafer-Glusman E, Choi M. Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study. Blood Adv. 2023 Sep 26;7(18):5294-5303. doi: 10.1182/bloodadvances.2023010236. PubMed 37315225 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Feb 2021, 34 months.

Results were first posted in Mar 2022, 1 year 1 month after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 34 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2018
First posted
Mar 12, 2018
StartActual
Apr 17, 2018
Primary completionActual
Feb 26, 2021
CompletionEst.
Apr 5, 2029
Results first posted
Mar 28, 2022
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Wojewodzki Szpital Specjalistyczny im Janusza Korczaka · Koszalin, Poland
Show 1 removed
  • Wojewodzki Szpital Specjalistyczny im Janusza Korczaka · Słupsk, Poland
Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    1 site added, 1 site removed
    Show site
    • Wojewodzki Szpital Specjalistyczny im Janusza Korczaka · Koszalin, Poland
    Show 1 removed
    • Wojewodzki Szpital Specjalistyczny im Janusza Korczaka · Słupsk, Poland
    + 1 other change: verification date
  2. Sep 28, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03462719
Collaborators
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Mar 12, 2018
Start date
Apr 17, 2018
Primary completion
Feb 26, 2021
Completion
Apr 5, 2029 (estimated)
Results posted
Mar 28, 2022
Last update
Nov 3, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibrutinib · Venetoclax

Start the discussion